Risultati per: Diagnosi e gestione della steatosi epatica non alcolica (NAFLD)

La gran parte degli accessi al PS legata ai sintomi del cancro

E’ il “Fibroscan”, per individuare patologie croniche

E’ il “Fibroscan”, per individuare patologie croniche

Medici e pazienti, ‘più formazione e rendere le terapie disponibili per tutti’

Non solo un problema dei bimbi ma “attenzione all’autodiagnosi”

We have read with interest the study from Simon et al, where the authors observed a higher mortality rate among patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) compared with reference controls without NAFLD.1 Importantly, mortality rates exhibited a significant increase as the severity of NAFLD worsened, that is, from simple steatosis, non-fibrotic nonalcoholic steatohepatitis (NASH), non-cirrhotic fibrosis (ie, F1–F3, with or without NASH) to cirrhosis. The leading causes of death were attributable to extrahepatic cancers and liver cirrhosis, while cardiovascular disease and hepatocellular carcinoma had a comparatively lesser impact. This extensive study of patients with NAFLD reveals higher mortality rates across different NAFLD stages but does not stratify causes of death within the respective pre-cirrhotic fibrosis stages (F0–F3). Owing to the long natural history of NAFLD, for example, patients with F0 and F1 may never experience liver-related events.2–4 For that…

I risultati del progetto Iss “Veterani in Sella”

I risultati del progetto Iss “Veterani in Sella”

Tra gli effetti indesiderati le disfunzioni di tiroide e ipofisi